Price Alert

Regeneron Pharmaceuticals... (REGN)

NASDAQ: REGN · Real-Time Price · USD

563.90

8.39 (1.51%)

At close: Sep 26, 2025, 3:59 PM

564.50

0.11%

After-hours: Sep 26, 2025, 07:59 PM EDT

Regeneron Pharmaceuticals Statistics

Share Statistics

Regeneron Pharmaceuticals has 104.17M shares outstanding. The number of shares has increased by -2.09% in one year.

Shares Outstanding	104.17M
Shares Change (YoY)	-2.09%
Shares Change (QoQ)	-1.27%
Owned by Institutions (%)	86.23%
Shares Floating	97.89M
Failed to Deliver (FTD) Shares	2
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 2.99M, so 2.77% of the outstanding shares have been sold short.

Short Interest	2.99M
Short % of Shares Out	2.77%
Short % of Float	2.92%
Short Ratio (days to cover)	3.11

Valuation Ratios

The PE ratio is 17.42 and the forward PE ratio is 13.82. Regeneron Pharmaceuticals's PEG ratio is 1.68.

PE Ratio	17.42
Forward PE	13.82
PS Ratio	5.41
Forward PS	4.1
PB Ratio	2.62
P/FCF Ratio	20.97
PEG Ratio	1.68

Financial Ratio History

Enterprise Valuation

Regeneron Pharmaceuticals has an Enterprise Value (EV) of 77.08B.

EV / Sales	5.43
EV / EBITDA	14.49
EV / EBIT	17.44
EV / FCF	21.03

Financial Position

The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.09.

Current Ratio	4.73
Quick Ratio	3.95
Debt / Equity	0.09
Debt / EBITDA	0.51
Debt / FCF	0.74
Interest Coverage	75.61

Financial Efficiency

Return on Equity is 15.03% and Return on Invested Capital is 11.39%.

Return on Equity	15.03%
Return on Assets	11.69%
Return on Invested Capital	11.39%
Revenue Per Employee	$936.93K
Profits Per Employee	$291.11K
Employee Count	15,158
Asset Turnover	0.38
Inventory Turnover	0.79

Taxes

Income Tax	367.3M
Effective Tax Rate	7.68%

Stock Price Statistics

The stock price has increased by -45.92% in the last 52 weeks. The beta is 0.35, so Regeneron Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.35
52-Week Price Change	-45.92%
50-Day Moving Average	569.03
200-Day Moving Average	613.06
Relative Strength Index (RSI)	46.72
Average Volume (20 Days)	1,111,267

Income Statement

In the last 12 months, Regeneron Pharmaceuticals had revenue of 14.2B and earned 4.41B in profits. Earnings per share was 40.9.

Revenue	14.2B
Gross Profit	11.75B
Operating Income	4.17B
Net Income	4.41B
EBITDA	5.32B
EBIT	4.84B
Earnings Per Share (EPS)	40.9

Full Income Statement

Balance Sheet

The company has 2.49B in cash and 2.7B in debt, giving a net cash position of -216.2M.

Cash & Cash Equivalents	2.49B
Total Debt	2.7B
Net Cash	-216.2M
Retained Earnings	31.67B
Total Assets	38.22B
Working Capital	13.19B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.42B and capital expenditures -755.9M, giving a free cash flow of 3.66B.

Operating Cash Flow	4.42B
Capital Expenditures	-755.9M
Free Cash Flow	3.66B
FCF Per Share	33.96

Full Cash Flow Statement

Margins

Gross margin is 82.74%, with operating and profit margins of 29.39% and 31.07%.

Gross Margin	82.74%
Operating Margin	29.39%
Pretax Margin	33.66%
Profit Margin	31.07%
EBITDA Margin	37.45%
EBIT Margin	29.39%
FCF Margin	25.8%

Dividends & Yields

REGN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	5.74%
FCF Yield	4.77%

Dividend Details

Analyst Forecast

The average price target for REGN is $790.5, which is 40.2% higher than the current price. The consensus rating is "Buy".

Price Target	$790.5
Price Target Difference	40.2%
Analyst Consensus	Buy
Analyst Count	21

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$204.5
Lynch Upside	-63.73%
Graham Number	500.32
Graham Upside	-11.28%

Scores

Altman Z-Score	6.94
Piotroski F-Score	5